Here are four key notes:
1. Epigenomics developed the test, and it is available in the U.S. through a joint commercialization agreement with Polymedco.
2. The Epi proColon test detects Epigenomics proprietary Septin9 DNA methylation biomarker for colorectal cancer in cell-free DNA circulating in blood.
3. The test was approved by the FDA in April.
4. Epi proColon provides an alternative to stool testing or colonoscopy.
More articles on GI/endoscopy:
FMT helps reduce recurring episodes of C. Diff in children: 4 findings
GIQuIC registry hits 3M colonoscopy cases: 5 things to know
Certain body sugars help prevent UC & colon cancer — 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.